Product NewsNovozymes Biopharma Enters Agreement with a Leading Vaccine Company to Conduct Research on a Novel Subunit Vaccine Complex Based on Albumin Fusion Technology
Product NewsExclusive Interview: Dr Darrell Sleep Talks to SelectScience about Albumin and its Power to Boost Existing Drugs
Product NewsNovozymes Biopharma to Offer Drug-Albumin Conjugation Platform in Collaboration with ThioLogics
Product NewsNovozymes' Half-Life Extension Technology Reaches Landmark Milestone as GlaxoSmithKline's Albiglutide is Granted FDA Marketing Approval
Product NewsNovozymes Biopharma to Present Latest Advances in Drug Delivery Technology at Controlled Release Society Meeting
Product NewsNovozymes Biopharma to Unveil New Research into the Production of Proteins with Extended Circulatory Half-Life at Next Generation Protein Therapeutics Summit
Product NewsNovozymes Biopharma Collaborates with the University of Oslo to Develop Enhanced Albumin Fusion Technology that Tailors the Half-life of Proteins
